Anatara Lifesciences Recruitment for Irritable Bowel Syndrome Trial Ongoing

MT Newswires Live

2024/10/18

Anatara Lifesciences (ASX:ANR) said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.

The target participant number for the trial is 60 to 100, the filing said.

The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2476496517"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2476496517\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2476496517?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-18 09:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476496517","market":"fut","top_or_hot":-1,"title":"Anatara Lifesciences Recruitment for Irritable Bowel Syndrome Trial Ongoing","media":"MT Newswires Live","content":"<html><body><p> Anatara Lifesciences (ASX:ANR) said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.</p><p>The target participant number for the trial is 60 to 100, the filing said.</p><p>The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anatara Lifesciences Recruitment for Irritable Bowel Syndrome Trial Ongoing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnatara Lifesciences Recruitment for Irritable Bowel Syndrome Trial Ongoing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-18 09:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Anatara Lifesciences (ASX:ANR) said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.</p><p>The target participant number for the trial is 60 to 100, the filing said.</p><p>The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANR.AU","symbol_name":"ANATARA LIFESCIENCES LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2476496517","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476496517","pubTimestamp":1729213887,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Anatara Lifesciences  said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.The target participant number for the trial is 60 to 100, the filing said.The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANR.AU":"ANATARA LIFESCIENCES LTD","XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","BK7067":"生物科技","BK7508":"医药生物股","XJO.AU":"标普/澳交所 200指数"},"translate_title":"Anatara Lifesciences招募肠易激综合征试验正在进行中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAO.AU":0.9,"ANR.AU":0.9,"XKO.AU":0.9,"XJO.AU":0.9},"content_text":"Anatara Lifesciences (ASX:ANR) said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.The target participant number for the trial is 60 to 100, the filing said.The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}